Integrated Preclinical Development

One coordinated path connects compound supply and custom synthesis with exploratory non-GLP studies and partner-coordinated GLP safety studies, delivering a decision-ready pre-IND data package.

Start a Project

Core Capabilities

Three execution workstreams define what the program needs. Disease areas, models, and species remain separate decisions.

Pharmacology & Efficacy

In vitro and in vivo pharmacology, disease-model efficacy, PK/PD, biomarkers, and mechanism-linked endpoints.

Disease models, PK/PD, Biomarkers
Explore efficacy
Microscopic view supporting oncology and efficacy research

Organizing Workflow As One Program

One coordinated workflow connects material readiness, study planning, partner selection, logistics, execution, and reporting. It reduces handoffs, duplicated work, cross-border shipping burden, and multi-vendor overhead.

  1. Compound readiness & material routing

    Coordinate supply, custom synthesis, characterization, formulation, and local or regional sourcing where practical. Study material can move directly to the selected laboratory with fewer logistics steps and cross-border transfers.

  2. Study design & partner strategy

    Turn development goals into a practical study plan and match models, endpoints, species, analytical capabilities, and quality needs with suitable partner resources. Reduce vendor screening and fragmented decisions.

  3. Coordinated laboratory execution

    Coordinate laboratories, material delivery, technical handoffs, study schedules, and cross-platform dependencies through one project interface. Reduce repeated communication, logistics burden, and execution delays.

  4. Integrated data & decision package

    Consolidate study outputs, reports, and cross-study findings into one project package. Make the next development decision without rebuilding information across multiple vendors or repeating avoidable work.

Preclinical Development Pathway

Coordinated work and typical deliverables, aligned to your program.

Scroll horizontally to explore all five stages.

Project
coordination

Material &
study design

Study
execution

Typical
deliverables

Compound & Material Readiness

Study Strategy

Pharmacology & Efficacy

DMPK & Bioanalysis

Safety & IND-Enabling

Planning, laboratory matching, material, timeline & data coordination
Material & analytical readiness
Protocol & endpoint design
Study material & sample coordination
Material preparation
Model & partner selection
Pharmacology & efficacy
DMPK & bioanalysis
Safety / IND-enabling
  • CoA & SDS
  • Route / analytical package
  • Material & shipment plan
  • Development plan
  • Protocol & endpoints
  • Partner & execution plan
  • Study protocol
  • Efficacy reports
  • Raw data & statistics
  • Bioanalytical method
  • PK / TK datasets
  • ADME / metabolite outputs
  • Toxicology reports
  • Safety pharmacology
  • TK / pathology outputs
Integrated pre-IND data package
Illustrative workflow; activities may overlap. Scope, deliverables and GLP requirements are confirmed per program.

Therapeutic Areas

Start with the disease biology. Open a therapeutic area to see the corresponding model layer, then continue to a defined model detail.

Oncology & Immuno-OncologyTumor efficacy, tumor–immune biology, humanized immune systems, and translational oncology study design.
Models
Immunology & InflammationImmune-mediated disease models with clinical, cytokine, cellular, histology, and tissue-level readouts.
Models
Metabolic DiseaseObesity, diabetes, incretin biology, MASH, and related metabolic efficacy or exposure questions.
Models
Cardiovascular & CerebrovascularFunctional, imaging, behavioral, biomarker, and pathology readouts for cardiovascular and stroke programs.
Models
NeuroscienceBehavioral, neurochemical, biomarker, and tissue endpoints across neurodegenerative and neuropsychiatric programs.
Models
Renal & Urinary DiseaseKidney injury, fibrosis, nephropathy, renal hypertension, and immune-mediated renal disease models.
Models
Respiratory & Pulmonary DiseasePulmonary fibrosis, acute lung injury, asthma, and other respiratory disease models with tissue and biomarker readouts.
Models
Liver & Hepatic DiseaseLiver fibrosis, metabolic liver disease, hepatitis, drug-induced injury, and related hepatic efficacy programs.
Models

Featured Models

Defined model pages connect therapeutic context with species, study format, typical applications, and endpoints.

PDX

PDX studies use patient-derived tumor tissue in immunodeficient mice for oncology efficacy, PK/PD, biomarker, and tissue-analysis work.

PBMC Humanized

Human PBMC engraftment in NOG-family mice provides a human immune-cell context for T-cell-focused immuno-oncology research and preclinical pharmacology.

HSC Humanized

The documented HSC-humanized platform engrafts human CD34+ hematopoietic stem cells into NOG-EXL mice expressing human GM-CSF and IL-3.

CIA

The documented CIA platform uses DBA/1 mice and type II collagen immunization for rheumatoid-arthritis pharmacology studies involving T- and B-cell biology.

MASH

Diet-induced MASH/NASH models, including MCD-, AMLN-, and HFD/STZ-based study formats, support metabolic liver-disease pharmacology with histology, fibrosis, biomarker, and PK/PD endpoints.

DIO

High-fat diet-induced obesity models are available in mice and rats for metabolic-disease pharmacology and integrated exposure or biomarker-oriented studies.

DSS Colitis

The documented inflammatory-bowel-disease platform includes DSS-induced acute and chronic colitis mouse models for preclinical pharmacology studies.

MCAO

Mouse and rat middle cerebral artery occlusion studies use a suture-occlusion approach to model cerebral ischemia for stroke-focused preclinical research.

MODEL LIBRARY

In Vivo Species Coverage

DempoChem provides a wide variety of in vivo laboratory animal species through its high-quality network of industry partners.

  • Mouse
  • Rat
  • NHP
  • Dog
  • Rabbit
  • Minipig
  • Guinea Pig
View detailed in vivo platforms

Facilities & Scientific Infrastructure

Programs are placed with selected partner facilities matched to the study type, species, model, instrumentation, quality framework, and scientific team required.

Laboratory environment representing partner-facility review
Laboratory environments
Scientist working in a controlled laboratory environment
Controlled laboratory operations
Scientist operating analytical laboratory equipment
Analytical instrumentation

Facility views provide representative context. The executing site and site-specific documentation are confirmed during technical review.

Quality & Compliance

AAALAC International

Access to selected partner animal programs operating within AAALAC-accredited systems, where required and confirmed for the assigned facility.

OECD GLP

GLP study execution can be placed with qualified partner laboratories; the exact site, scope, and quality framework are confirmed per study.

FDA GLP Experience

Selected partner laboratories include facilities with FDA GLP inspection experience. The relevant inspection history is verified for the assigned site.

IACUC Oversight

Animal protocols are reviewed through the executing institution’s ethics and animal-care oversight process.

Veterinary Oversight

Partner facilities maintain veterinary supervision appropriate to the species, procedures, housing, and study design.

Animal Welfare

Animal care, welfare monitoring, and periodic facility review are part of partner-site qualification and study planning.

Accreditation status, inspection history, GLP scope, ethics oversight, veterinary arrangements, and animal-welfare procedures are verified for the laboratory assigned to each program.

Discuss Your Program

Tell us what you need help with, and our team will follow up to discuss the appropriate study support.Required fields are marked with an asterisk(*).

Area of interest

Tell us what you need help with. Include any model preferences or timing requirements if known.

Your contact